Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a Healthcare company (Biotechnology) with a market capitalization of $194M. The Maz Rating grades it against the other companies in its sector.
Inhibikase Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.38, Inhibikase Therapeutics, Inc. trades at 1.4x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -40.5%, return on invested capital of -39.9% and a free cash flow yield of -25.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 15.34. Over the past 52 weeks the share price ranged from $1.37 to $2.61, with a beta of 0.94.
Inhibikase Therapeutics, Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 1 Buy and 2 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.